STOCKHOLM — In the treatment of type 2 diabetes, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) show independent benefits that complement ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 and GLP-1 agents were linked to lower risk of kidney-related outcomes for adults with type 2 diabetes and ...

SGLT2 inhibitors significantly lowered the risk of death, major adverse kidney events (MAKE), and major adverse cardiovascular events (MACE) in people with type 2 diabetes and acute kidney disease, ...

New data from the landmark FLOW trial, which linked the glucagon peptide 1 (GLP-1) receptor agonist semaglutide with significant kidney outcomes in patients with type 2 diabetes (T2D) and chronic ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SGLT2 inhibitors cut the risk for adverse CV outcomes ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

A recent study published in the Journal of the American Medical Association revealed that the use of sodium-glucose ...

HOUSTON -- SGLT2 inhibitors may hold a benefit for a wider pool of patients with chronic kidney disease (CKD) than previously thought, a pair of meta-analyses indicated. SGLT2 inhibitors helped to ...

Observational study data suggest that SGLT2 inhibitor use reduces risks for kidney and cardiovascular events even in patients with an eGFR less than 15 mL/min/1.73 m2 who have type 2 diabetes.